Table 2. Association of the atopic march loci with eczema alone and asthma alone in the ALSPAC cohort.

SNP ID	Chr	Locus	Original discovery*	EA	AA	Atopic march			Eczema, no asthma			Asthma, no eczema
						OR	95% CI	P value	OR	95% CI	P value	OR	95% CI	P value
rs9357733	6	EFHC1	Atopic march	a	g	1.27	1.07–1.52	0.0072	0.98	0.83–1.17	0.84	0.97	0.82–1.14	0.71
rs993226	12	SLC6A15/TMTC2	Atopic march	g	t	1.43	1.06–1.94	0.020	0.82	0.55–1.21	0.31	0.77	0.53–1.13	0.18
FLG combined†	1	FLG	Eczema	mut	wt	2.89	2.12–3.92	1.2 × 10−11	1.99	1.42–2.80	7.8 × 10−5	0.79	0.51–1.23	0.29
rs17690965	5	IL4/KIF3A	Eczema	c	g	1.18	1.02–1.37	0.025	1.12	0.96–1.31	0.15	1.03	0.89–1.19	0.72
rs479844	11	OVOL1	Eczema	g	a	1.24	1.08–1.42	0.0019	1.24	1.07–1.43	0.0032	1.00	0.87–1.14	0.95
rs2155219	11	C11orf30/LRRC32	Eczema	t	g	1.23	1.08–1.39	0.0016	1.12	0.98–1.28	0.097	1.05	0.92–1.19	0.49
rs10445308	17	IKZF3	Asthma	c	t	1.13	0.99–1.29	0.066	0.93	0.81–1.06	0.27	1.30	1.14–1.48	6.5 × 10−5

AA, alternative allele; EA, effect allele; CI, confidence interval; OR, odds ratio.

^*Allergic phenotype first associated with SNP.

^†ORs for FLG combined were estimated based on the two most frequent disease-causing mutations FLG R501X and FLG 2282del4; mut, mutated allele; wt, wild-type allele.